One-Stop prostate cancer diagnosis: new device combines MRI and biopsy
NCT ID NCT05362032
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a new device called OmnEcoil can safely and effectively combine two separate prostate cancer tests—MRI and biopsy—into a single procedure. About 45 men aged 45 and older with elevated PSA or abnormal exams will participate. The goal is to see if this approach simplifies diagnosis and provides clear tissue samples for cancer detection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Shockwaves may speed up erectile recovery after prostate cancer surgery
- Could a common blood pressure drug help fight prostate cancer?
- Can brain waves predict bladder control after prostate surgery?
- New PET tracer could reveal hidden prostate cancer
- New PET-MRI tracer could sharpen prostate cancer biopsy accuracy
- New PET tracer could spot cancers that standard scans overlook